Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review.
Curr Opin Oncol., Nov;23(6):594-600 (2011)
Current and emerging targeted therapies for metastatic breast cancer.
Cancer., Jun;118(12):3014-25 (2012)
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.
J. Clin. Oncol., Dec;29(34):4491-7 (2011)
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
J. Natl. Cancer Inst., Jan;104(2):159-62 (2012)
Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial.
Clin. Breast Cancer., Apr;12(2):81-6 (2012)
Breast cancer management: opportunities and barriers to an individualized approach.
Oncologist., 16 Suppl 1:20-2 (2011)
MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer.
Trends Mol Med., Jun;17(6):313-9 (2011)
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
J. Clin. Oncol., Sep;29(25):3366-73 (2011)
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
Breast., Apr;19(2):92-6 (2010)
Adjuvant therapy of triple negative breast cancer.
Breast Cancer Res. Treat., Apr;120(2):285-91 (2010)
In newly diagnosed breast cancer, screening MRI of the contralateral breast detects mammographically occult cancer, even in elderly women: the mayo clinic in Florida experience.
Breast J., 16(2):118-26 (2010)
Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.
Breast Cancer Res. Treat., Jun;121(2):261-71 (2010)
Breast cancer in Latinas: gene expression, differential response to treatments, and differential toxicities in Latinas compared with other population groups.
Oncologist., 15(5):466-75 (2010)
Changes to adjuvant systemic therapy in breast cancer: a decade in review.
Clin. Breast Cancer., Jun;10(3):196-208 (2010)
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
J. Clin. Oncol., Oct;28(28):4307-15 (2010)
Treatment options for patients with triple-negative breast cancer.
J Hematol Oncol., 3:42 (2010)
N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.
Ann. Oncol., Mar;21(3):493-7 (2010)
Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
Mol. Cancer Ther., Aug;8(8):2086-95 (2009)
Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Clin Ther., Aug;31(8):1619-40 (2009)
Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer.
Oncologist., Nov;14(11):1061-9 (2009)